Search

How biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease. Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined. Anti-VEGF treatments have...

The National Institutes of Health (NINDS, NIA) provides funding for projects in our lab. We are also sincerely grateful to the patients, family members, and caregivers who donated their time, brains, and biospecimens for biomedical research. __________________________________________________________...

Staying Boston Strong! Improving ophthalmic disaster readiness and response planning. Focus on Ocular Trauma • Key Lessons Learned • Benchmark protocols for managing open-globe repairs April 15, 2013: Residents, fellows and faculty from Mass. Eye and Ear and Harvard Medical School (HMS) clinical...

Designed for practicing ophthalmologists, Eye Insights provides practical and relevant best practice information from Mass. Eye and Ear specialists in an easy-to-read format. Published twice a year, this clinical newsletter is mailed to 18,000 practicing ophthalmologists nationwide and features a...

While significant progress has been achieved in treating retinal diseases, researchers at Mass. Eye and Ear/Schepens Eye Research Institute remain deeply committed to improving current therapies, refining diagnostic tools, and developing new therapies that leverage advances in biotechnology and...

Quis autem repudiandae consequatur illo doloribus ratione. Omnis amet aut vitae ad accusamus. Tempore Quia Ut Ullam Nihil Aspernatur Eos. Debitis omnis ut dolore excepturi vel doloremque odit provident. Exercitationem maxime sit. Sapiente temporibus et magnam facilis impedit accusantium deserunt...